Soluble B-cell activation marker of sCD27 and sCD30 and future risk of B-cell lymphomas: A nested case-control study and meta-analyses

Fatemeh Saberi Hosnijeh, Lutzen Portengen, Florentin Späth, Ingvar A. Bergdahl, Beatrice Melin, Amalia Mattiello, Giovanna Masala, Carlotta Sacerdote, Alessio Naccarati, Vittorio Krogh, Rosario Tumino, Marc Chadeau-Hyam, Paolo Vineis, Roel Vermeulen

Research output: Contribution to journalArticle

Abstract

Prediagnostic serum/plasma concentrations of B-cell activation markers have been associated with future risk of B-cell lymphomas (BCL) in HIV-infected patients and in the general population. Current evidence for the general population is however limited and relies on relatively small numbers of observations, especially for specific histologies. We carried out a nested case-control study, including 218 BCL and 218 matched controls, within two prospective cohorts, to investigate the association between plasma levels of soluble (s)CD27 and sCD30 and future risk of BCL, and main histologic subtypes separately. To expand the evidence further, we performed meta-analyses of the published data on these associations from prospective studies among the general population. Our study revealed a significant relationship between sCD30 concentration and BCL risk (OR = 0.86, 1.53, 1.76, for the 2nd-4th quartiles respectively, p trend = 0.01). Similar increased risks were observed for diffuse large B-cell lymphoma and follicular lymphoma. Analyses of sCD27 blood concentrations did not show significant associations with BCL, (OR = 0.90, 1.26, 1.65 for the 2nd-4th quartiles, respectively, p trend = 0.17), but significant associations were observed for chronic lymphocytic leukaemia and for the group of "other BCL" subtypes. Our findings involving sCD30 were confirmed within our meta-analyses of five prospective cohorts, while results were more heterogeneous for sCD27 with the exception of CLL which was found consistently in all studies. Data to date suggest that chronic B-cell stimulation might be an important mechanism involved in B-cell lymphomagenesis both in HIV-infected and in the general population.

Original languageEnglish
Pages (from-to)2357-2367
Number of pages11
JournalInternational Journal of Cancer
Volume138
Issue number10
DOIs
Publication statusPublished - May 15 2016

Keywords

  • lymphoma
  • meta-analyses
  • prospective study
  • sCD27
  • sCD30

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Soluble B-cell activation marker of sCD27 and sCD30 and future risk of B-cell lymphomas: A nested case-control study and meta-analyses'. Together they form a unique fingerprint.

  • Cite this

    Hosnijeh, F. S., Portengen, L., Späth, F., Bergdahl, I. A., Melin, B., Mattiello, A., Masala, G., Sacerdote, C., Naccarati, A., Krogh, V., Tumino, R., Chadeau-Hyam, M., Vineis, P., & Vermeulen, R. (2016). Soluble B-cell activation marker of sCD27 and sCD30 and future risk of B-cell lymphomas: A nested case-control study and meta-analyses. International Journal of Cancer, 138(10), 2357-2367. https://doi.org/10.1002/ijc.29969